Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $645.9 million.

  • BridgeBio Pharma's Cash & Current Investments rose 5920.37% to $645.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.9 million, marking a year-over-year increase of 5920.37%. This contributed to the annual value of $681.1 million for FY2024, which is 5661.67% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Cash & Current Investments of $645.9 million as of Q3 2025, which was up 5920.37% from $756.9 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Cash & Current Investments peaked at $919.1 million during Q1 2021, and registered a low of $352.9 million during Q2 2023.
  • For the 5-year period, BridgeBio Pharma's Cash & Current Investments averaged around $575.3 million, with its median value being $547.4 million (2024).
  • In the last 5 years, BridgeBio Pharma's Cash & Current Investments plummeted by 4874.48% in 2023 and then skyrocketed by 5920.37% in 2025.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Cash & Current Investments stood at $393.9 million in 2021, then grew by 5.25% to $414.6 million in 2022, then increased by 4.89% to $434.9 million in 2023, then soared by 56.62% to $681.1 million in 2024, then dropped by 5.16% to $645.9 million in 2025.
  • Its last three reported values are $645.9 million in Q3 2025, $756.9 million for Q2 2025, and $540.6 million during Q1 2025.